One approach. Multiple diseases of decline
Our platform enables the body to produce therapeutic signals that naturally reach the brain and other tissues — with the potential to restore functions across memory, strength, and resilience.
programs
Our development programs
Alzheimer's Disease
Cancer-Related Cachexia
Age-Related Muscle Loss
Alzheimer's Disease
RTX-100
Preclinical · IND-enablind
Restoring signals linked to memory and cognitive function — helping people preserve memory, maintain independence, and stay connected to the people and places that define their lives.
Targeting pathways associated with cognitive decline
Designed to reach the brain without direct CNS intervention
Preclinical studies exploring memory-related outcomes
Cancer-Related Cachexia
RTX-200
Preclinical Research
Addressing severe weight and muscle loss leading to physical decline in cancer patients — supporting their ability to recover, tolerate therapy, and sustain quality of life.
Targeting pathways linked to muscle health
Potential to improve physical resilience
Exploring systemic effects beyond the brain
Age-Related Muscle Loss
Research Stage
Supporting strength, mobility, and resilience with aging — helping people maintain mobility, independence, and physical confidence as they age.
Targeting biological drivers of sarcopenia
Focused on maintaining physical function over time
Expanding platform applications into aging
